IXI vs. SBTX, COS, C4XD, DDDD, FUM, TRX, OKYO, AOR, SAR, and POLB
Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), Tissue Regenix Group (TRX), OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
IXICO vs. Its Competitors
IXICO (LON:IXI) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
IXICO has a net margin of -31.10% compared to SkinBioTherapeutics' net margin of -237.95%. IXICO's return on equity of -19.14% beat SkinBioTherapeutics' return on equity.
IXICO has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
IXICO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
IXICO received 97 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 71.64% of users gave IXICO an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
In the previous week, IXICO had 3 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 3 mentions for IXICO and 0 mentions for SkinBioTherapeutics. IXICO's average media sentiment score of 1.47 beat SkinBioTherapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the media.
56.0% of IXICO shares are owned by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 30.3% of IXICO shares are owned by company insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
IXICO beats SkinBioTherapeutics on 12 of the 15 factors compared between the two stocks.
Get IXICO News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:IXI) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy IXI Stock Free IXI Stock Alerts